Chen Meng, Jin Dacheng, Wang Bing, Gou Yun Jiu, Dong Xin Chun
Gansu University of Chinese Medicine, Lanzhou 730000, China.
Department of Thoracic Surgery, Gansu Provincial Hospital, No. 204 Donggang West Road, Lanzhou 730000, China.
Math Biosci Eng. 2020 Jan 17;17(3):2302-2309. doi: 10.3934/mbe.2020122.
The prognostic value of microRNAs for esophageal squamous cell carcinoma (ESCC) is still not be well identified. The microRNA expression profiles of 119 paired ESCC tissue samples and para-carcinoma tissues from GEO database under accession number of GSE43732. A mutation information based feature selection method was applied to identify the discriminative microRNAs between paired ESCC tissues and para-carcinoma tissues. In para-carcinoma tissues, patients had better survival with higher has-miR-410 (log-rank p = 0.0123), has-miR-411-5p (log-rank p = 0.0152), has-miR-193b-5p (log-rank p = 0.0188) and has-miR-4486 (log-rank p = 0.0307) expression levels. When compared with para-carcinoma tissues, there has more correlations between miRNA expression levels and survival in tumor tissues. We identified 20 potential miRNAs associated with prognosis. Besides, a heatmap was draw to explore miRNA expression levels in tumor tissues and survival. The present study identified 24 miRNAs in 119 paired ESCC tissue samples and para-carcinoma tissues, including 4 miRNAs in para-carcinoma tissues and 20 in tumor tissues, respectively. The dysregulation of these miRNAs were associated with different outcomes. We thought this study could provide novel noninvasive early biomarkers for ESCC patients.
微小RNA对食管鳞状细胞癌(ESCC)的预后价值仍未得到充分明确。从GEO数据库中获取了119对ESCC组织样本和癌旁组织的微小RNA表达谱,登录号为GSE43732。应用一种基于突变信息的特征选择方法来识别配对的ESCC组织和癌旁组织之间具有鉴别性的微小RNA。在癌旁组织中,具有较高的has-miR-410(对数秩检验p = 0.0123)、has-miR-411-5p(对数秩检验p = 0.0152)、has-miR-193b-5p(对数秩检验p = 0.0188)和has-miR-4486(对数秩检验p = 0.0307)表达水平的患者生存情况较好。与癌旁组织相比,肿瘤组织中微小RNA表达水平与生存之间的相关性更强。我们鉴定出了20种与预后相关的潜在微小RNA。此外,绘制了一张热图以探究肿瘤组织中的微小RNA表达水平与生存情况。本研究在119对ESCC组织样本和癌旁组织中鉴定出了24种微小RNA,其中癌旁组织中有4种,肿瘤组织中有20种。这些微小RNA的失调与不同的预后结果相关。我们认为本研究可为ESCC患者提供新的非侵入性早期生物标志物。